FDA approves Amvuttra (vutrisiran) for transthyretin amyloid cardiomyopathy (ATTR-CM)

Alnylam Pharmaceuticals/Amvuttra (vutrisiran)

The FDA approved Amvuttra for adult patients with ATTR-CM, a rare genetic disease in which transthyretin protein misfolds and damages the heart. Amvuttra uses RNA interference to reduce TTR production in the liver, slowing disease progression.